Foundation Medicine

For patients and their families navigating a cancer diagnosis, the journey can be filled with uncertainty and complex decisions. Understanding the unique genomic drivers of an individual's cancer is a critical step towards personalized treatment, but this information has not always been readily accessible. Foundation Medicine was founded to address this challenge head-on. We empower physicians and patients with comprehensive genomic profiling (CGP) to unlock the molecular information within a tumor. Our services provide a deep understanding of the genomic mutations that fuel cancer, transforming the approach to cancer care from a one-size-fits-all model to one that is precisely tailored to each patient's specific needs. Our goal is to make this level of detailed insight a standard part of every patient's journey, enabling more informed decisions and expanding potential treatment avenues.

Our customers, who include oncologists, researchers, and biopharmaceutical companies, are at the heart of everything we do. For physicians, our proven portfolio of tests, including FoundationOne®CDx for solid tumors, FoundationOne®Liquid CDx for a blood-based option, and FoundationOne®Heme for hematologic malignancies, provides actionable insights to guide treatment strategies. These tests analyze hundreds of cancer-related genes to identify clinically relevant alterations, matching patients with targeted therapies, immunotherapies, and potential clinical trials. For our biopharma partners, we support the entire drug development lifecycle, from discovery to the launch of new therapies. By collaborating with the broader cancer community, we strive to accelerate the development of new treatments and ensure that more people around the world can benefit from the promise of precision cancer care. We are committed to not just providing a test, but a comprehensive service that includes decision support and technology solutions to ultimately improve patient outcomes.